Clinical characteristics of the study patients and responses to pembrolizumab
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . |
|---|---|---|---|---|
| Disease stage at the time of study | Stage IIB mycosis fungoides | Stage IVB mycosis fungoides | Stage IIB mycosis fungoides | Stage IVB mycosis fungoides |
| Large cell transformation | Yes | Yes | Yes | Yes |
| Sex, age, y | Male, 57 | Male, 75 | Male, 69 | Female, 25 |
| Prior lines of systemic therapy | 3 | 9 | 4 | 1 |
| Relevant medical history | Allogeneic hematopoietic stem cell transplant | Orthotopic cardiac transplant | ||
| Total cycles of treatment* | Pembrolizumab + IFNγ: 6 Pembrolizumab alone: +36 | 2 (4 mo apart because of pneumonitis) | 6 | NA |
| Reason for treatment discontinuation | NA | Recurrent immune-related pneumonitis | Disease progression | NA |
| Duration of response | First round (pembrolizumab + IFNγ): 12 wk; second round (pembrolizumab + local XRT): 110 wk | 12 wk | 9 wk | NA |
| . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . |
|---|---|---|---|---|
| Disease stage at the time of study | Stage IIB mycosis fungoides | Stage IVB mycosis fungoides | Stage IIB mycosis fungoides | Stage IVB mycosis fungoides |
| Large cell transformation | Yes | Yes | Yes | Yes |
| Sex, age, y | Male, 57 | Male, 75 | Male, 69 | Female, 25 |
| Prior lines of systemic therapy | 3 | 9 | 4 | 1 |
| Relevant medical history | Allogeneic hematopoietic stem cell transplant | Orthotopic cardiac transplant | ||
| Total cycles of treatment* | Pembrolizumab + IFNγ: 6 Pembrolizumab alone: +36 | 2 (4 mo apart because of pneumonitis) | 6 | NA |
| Reason for treatment discontinuation | NA | Recurrent immune-related pneumonitis | Disease progression | NA |
| Duration of response | First round (pembrolizumab + IFNγ): 12 wk; second round (pembrolizumab + local XRT): 110 wk | 12 wk | 9 wk | NA |
Pembrolizumab was administered at the standard dose of 200 mg every 3weeks in all patients; patient 1 received IFNγ subcutaneously 3 times/wk per clinical trial protocol available at clinicaltrials.gov (NCT03063632).